272 related articles for article (PubMed ID: 21359582)
1. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study.
Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
Diabetologia; 2011 Jun; 54(6):1308-17. PubMed ID: 21359582
[TBL] [Abstract][Full Text] [Related]
2. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.
Malmberg K; Rydén L; Wedel H; Birkeland K; Bootsma A; Dickstein K; Efendic S; Fisher M; Hamsten A; Herlitz J; Hildebrandt P; MacLeod K; Laakso M; Torp-Pedersen C; Waldenström A;
Eur Heart J; 2005 Apr; 26(7):650-61. PubMed ID: 15728645
[TBL] [Abstract][Full Text] [Related]
3. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.
Ritsinger V; Malmberg K; Mårtensson A; Rydén L; Wedel H; Norhammar A
Lancet Diabetes Endocrinol; 2014 Aug; 2(8):627-33. PubMed ID: 24831989
[TBL] [Abstract][Full Text] [Related]
4. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
Eur Heart J; 2008 Jan; 29(2):166-76. PubMed ID: 18156614
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial.
Mellbin LG; Malmberg K; Waldenström A; Wedel H; Rydén L;
Heart; 2009 May; 95(9):721-7. PubMed ID: 19029171
[TBL] [Abstract][Full Text] [Related]
6. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
7. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study.
Malmberg K; Norhammar A; Wedel H; Rydén L
Circulation; 1999 May; 99(20):2626-32. PubMed ID: 10338454
[TBL] [Abstract][Full Text] [Related]
8. [Metabolic control by means of insulin in patients with type 2 diabetes and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity--secondary publication].
Gustafsson I; Malmberg K; Rydén L; Wedel H; Birkeland K; Bootsma A; Dickstein K; Efendic S; Fisher M; Hamsten A; Herlitz J; Hildebrandt PR; MacLeod K; Laakso M; Torp-Pedersen CT; Waldenström A;
Ugeskr Laeger; 2006 Feb; 168(6):581-4. PubMed ID: 16476220
[TBL] [Abstract][Full Text] [Related]
9. Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study.
Bromage DI; Godec TR; Pujades-Rodriguez M; Gonzalez-Izquierdo A; Denaxas S; Hemingway H; Yellon DM
Cardiovasc Diabetol; 2019 Dec; 18(1):168. PubMed ID: 31815634
[TBL] [Abstract][Full Text] [Related]
10. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C
Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618
[TBL] [Abstract][Full Text] [Related]
11. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
12. Self-rated health predicts outcome in patients with type 2 diabetes and myocardial infarction: a DIGAMI 2 quality of life sub-study.
Venskutonyte L; Brismar K; Öhrvik J; Rydén L; Kjellström B
Diab Vasc Dis Res; 2013 Jul; 10(4):361-7. PubMed ID: 23673377
[TBL] [Abstract][Full Text] [Related]
13. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort study.
Jørgensen CH; Gislason GH; Andersson C; Ahlehoff O; Charlot M; Schramm TK; Vaag A; Abildstrøm SZ; Torp-Pedersen C; Hansen PR
Cardiovasc Diabetol; 2010 Sep; 9():54. PubMed ID: 20843380
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
[TBL] [Abstract][Full Text] [Related]
15. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
16. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction.
Malmberg K; Rydén L; Hamsten A; Herlitz J; Waldenström A; Wedel H
Eur Heart J; 1996 Sep; 17(9):1337-44. PubMed ID: 8880018
[TBL] [Abstract][Full Text] [Related]
17. Satisfaction with glucose-lowering treatment and well-being in patients with type 2 diabetes and myocardial infarction: a DIGAMI2 QoL sub-study.
Venskutonyte L; Brismar K; Rydén-Bergsten T; Rydén L; Kjellström B
Diab Vasc Dis Res; 2013 May; 10(3):263-9. PubMed ID: 23188892
[TBL] [Abstract][Full Text] [Related]
18. Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial.
Ghotbi AA; Køber L; Finer N; James WP; Sharma AM; Caterson I; Coutinho W; Van Gaal LF; Torp-Pedersen C; Andersson C
Diabetes Care; 2013 Nov; 36(11):3746-53. PubMed ID: 24089540
[TBL] [Abstract][Full Text] [Related]
19. Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry.
Ritsinger V; Lagerqvist B; Lundman P; Hagström E; Norhammar A
Diab Vasc Dis Res; 2020; 17(6):1479164120973676. PubMed ID: 33231125
[TBL] [Abstract][Full Text] [Related]
20. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus.
Genuth S
Ann Intern Med; 1996 Jan; 124(1 Pt 2):104-9. PubMed ID: 8554200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
